UTILITY OF ATHEROGENIC INDEX OF PLASMA AS A CARDIOVASCULAR RISK FACTOR IN SUB-CLINICAL HYPOTHYROID PATIENTS

Authors

  • Saqibah Rehman Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan
  • Usman Munir Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan
  • Qaiser Alam Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan
  • Zujaja Hina Haroon Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan
  • Muhammad Younas Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan
  • Muhammad Anwar Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan

DOI:

https://doi.org/10.69656/pjp.v20i2.1631

Keywords:

AIP, Hypothyroidism, Cardiovascular, Subclinical, Cardiovascular Disease, T3, T4, TSH

Abstract

Background: Atherogenic index of plasma (AIP) is a reliable indicator of the likelihood of developing atherosclerosis and coronary heart disease. The objective of this study was to assess the AIP as a cardiovascular risk factor in subclinical hypothyroid patients, in predicting cardiovascular risk in patients of subclinical hypothyroidism. Methods: This prospective, cross-sectional study was conducted at a tertiary care hospital-based laboratory. Patients with Thyroid Stimulating Hormone (TSH) values between 4.5–10 IU/L and normal T4 were enrolled in the study. The participants were tested after fasting 8–10 hours and at least 3 days of fat-free diet for lipid profile analyzed on an automated chemistry analyzer. Data were analysed using SPSS-22. The odds ratio test was used to assess the risk of outcome keeping 1 as a positive measure to encounter outcome. Results: A total of 170 patients were enrolled in the study. Their mean age was 44.7±10.8 years. The AIP results indicated 118 (69.4%) as high risk, 41 (24.1%) as intermediate risk, and 11 (6.4%) as low risk (p<0.001). The assessment of outcome risk results indicated a positive association of exposure to outcome in TSH value of 6–7 mIU/L as OR 2.15 (CI: 1.81–4.13) while TSH value of 8–9 mIU/L as OR 1.08 (CI: 0.71–2.16). Conclusion: Sub-clinical hypothyroidism is associated with a higher risk of AIP especially with TSH levels of 4–8 mIU/L and age group of <50 years.

Pak J Physiol 2024;20(2):7-10

Downloads

Download data is not yet available.

References

Salih MA, Salih SF. Proprotein convertase subtilisin and kexin type 9 in sub clinical hypothyroidism as a risk factor for cardiovascular disease. J Pharm Negat Res 2022;13(3):994–9.

Lamichhane A, Bista P, Pokhrel S, Bolakhe K, Joshi G, Aryal S, et al. Assessment of cardiovascular disease risk in females with subclinical hypothyroidism. J Lipids 2023;2023:4440275.

Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2002;12(5):421–5.

Simlai S, Kumar P, Mohapatra TK, Sharma P. Hypothyroidism induced lipid peroxidation and coronary hazard in Lucknow. J Evid Based Med Healthc 2020;7(49):2907–12.

Nanda N, Bobby Z, Hamide A. Association of thyroid stimulating hormone and coronary lipid risk factors with lipid peroxidation in hypothyroidism. Clin Chem Lab Med 2008;46(5):674–9.

Popa CD, Arts E, Fransen J, van Riel PL. Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators Inflamm 2012;2012:785946.

Chaulin AM, Grigorieva YV, Suvorova GN, Duplyakov DV. Methods for modeling hypothyroidism: classification and modeling principles. Mol Med 2021;19(4):19–26. [Article in Russian].

Luster M, Duntas LH, Wartofsky L, (Eds). The thyroid and its diseases. Cham, Switzerland: Springer; 2019.

Hussain A, Elmahdawi AM, Elzeraidi NE, Nouh F, Algathafi K. The effects of dyslipidemia in subclinical hypothyroidism. Cureus 2019;11(11):e6173.

Ejaz M, Kumar P, Thakur M, Bachani P, Naz S, Lal K. Comparison of lipid profile in patients with and without subclinical hypothyroidism. Cureus 2021;13(8):e17301.

Kanthe PS, Patil BS, Bagali S, Deshpande A, Shaikh GB, Aithala M. Atherogenic index as a predictor of cardiovascular risk among women with different grades of obesity. Int J Collab Res Intern Med Public Health 2012;4(10):1767–74.

Dobiasova M. AIP –atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek 2006;52(1):64–71.

Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci 2010;10(3):248–52.

Abid HA, Abid ZS, Abid SA. Atherogenic indices in clinical practice and biomedical research: a short review. Baghdad J Biochem Appl Biol Sci 2021;2(02):60–70.

Guo X, Ma L. Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterol-related inflammatory parameters as predictors. Coron Artery Dis 2023;34(1):66–77.

Al-Tai WF, Jaffer EM, Ali ZA. Evaluating the utility of plasma Atherogenic Index among several atherogenic parameters in patients with chronic renal failure on maintenance hemodialysis. J Fac Med Baghdad 2012;54(3):259–62.

Vanderpump MP, Tunbridge WM. Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid. 2002 Oct 1;12(10):839-47.

Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, Dadgarmoghaddam M. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Medical journal of the Islamic Republic of Iran. 2015;29:240.

James SR, Ray L, Ravichandran K, Nanda SK. High atherogenic index of plasma in subclinical hypothyroidism: Implications in assessment of cardiovascular disease risk. Indian Journal of Endocrinology and Metabolism. 2016 Sep 1;20(5):656-61.

Madhura NS, Shankar M, Narasimhappa S. Subclinical hypothyroidism (SH) and atherogenic index of plasma (AIP) in women: a case-control study from a tertiary Care Hospital in South India. Cureus. 2020 Sep 24;12(9).

Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012;172(10):799–809.

Inoue K, Ritz B, Brent GA, Ebrahimi R, Rhee CM, Leung AM. Association of subclinical hypothyroidism and cardiovascular disease with mortality. JAMA network Open 2020;3(2):e1920745.

Downloads

Published

30-06-2024

How to Cite

1.
Rehman S, Munir MU, Khan MQA, Haroon ZH, Younas M, Anwar M. UTILITY OF ATHEROGENIC INDEX OF PLASMA AS A CARDIOVASCULAR RISK FACTOR IN SUB-CLINICAL HYPOTHYROID PATIENTS. Pak J Phsyiol [Internet]. 2024 Jun. 30 [cited 2024 Jul. 20];20(2):7-10. Available from: https://pjp.pps.org.pk/index.php/PJP/article/view/1631